Following a low oxalate diet can not only limit individuals from eating foods they enjoy, but can also make it more difficult to maintain a nutritionally balanced diet. Results from the Nephure clinical study — a new prospective, double-blind, randomized, placebo-controlled, cross-over study — may help provide more options for those living a low oxalate lifestyle.
Nephure enzyme product may provide much-needed support for individuals following a low-oxalate diet as part of the , according to clinical trial results presented at the American Urology Association (AUA)’s 2019 National Meeting in May.
“Compliance with physician’s recommendations is imperative, but following dietary recommendations can be challenging for many individuals. A product that can help with compliance will offer value to everyone involved. We are delighted to share these results with the medical community, confirming the efficacy and potency of our oxalate-reducing enzyme to reduce urinary oxalate,” Helena Cowley, Chief Executive Officer of Captozyme Inc., said.
About the Nephure Clinical Study
The study, sponsored by Captozyme Inc., parent company of Entring, LLC — the distributors of Nephure — began in August 2018. Following screening and baseline evaluations, all study subjects were placed on a two-day high-oxalate diet lead-in, which resulted in an elevation of urinary oxalate to approximately 43mg/24 hours. Subjects were then randomized to one of two cross-over treatment sequences (Nephure™ to placebo or placebo to Nephure™) while maintaining the controlled oxalate packed, low-calcium meal plan consisting of standard Western meals with added spinach and rhubarb to provide additional levels of oxalate intake.